Effect of Steroids on the Progression of Alzheimer's Dementia: A Retrospective Chart Review

Overview

Journal Aging Med (Milton)

Specialty Geriatrics

Date 2025 Feb 19

PMID 39968005

Authors

Julijana Zoran Conic

Alexandra Chetty

Lily Chen

Audrey Marsh

Sean Barry

Rodney Pattabhi

Thomas Reske

Erwin Aguilar

Lobna Ali

Affiliations

Soon will be listed here.

Abstract

Objectives: Alzheimer's disease (AD) is a prevalent age-related neurodegenerative disease that affects millions of individuals in the United States. Neuroinflammation is a driver of the neurodegenerative changes that characterize AD, prompting interest in how inflammation can be modulated for treatment and prevention.

Methods: ICD-10 codes were quarried from electronic medical records to identify patients diagnosed with AD from 2012 to 2020. The patients were then divided into those who used systemic steroids and those who did not before the progression of their disease. Data on medication prescribed was used to measure the disease's progression. Clinical findings and laboratory results were collected to build a propensity score. Patients were followed until disease progression, death, or the last available visit. Kaplan-Meier curves and hazard ratios adjusted for the propensity score were used to compare the two groups.

Results: Of the 459 patients identified, 77 were included in the study, and 13 used steroids. Of the 77 patients included in the study, 59 had progression of their disease, and of those, five used steroids. The median time to progression was 408.00 (191.00, 979.00) days for the overall sample. The hazard ratio (HR) comparing the group using steroids to those not using steroids was 0.26 with a 95% CI of (0.1013, 0.673) and a value of 0.00064.

Conclusions: In our study, steroid use delayed the progression of dementia. Further study is needed to outline how steroids and anti-inflammatory medications can be used in the treatment and prevention of AD.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Gale S, Acar D, Daffner K . Dementia. Am J Med. 2018; 131(10):1161-1169. DOI: 10.1016/j.amjmed.2018.01.022. View

Dubois B, von Arnim C, Burnie N, Bozeat S, Cummings J . Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 2023; 15(1):175. PMC: 10571241. DOI: 10.1186/s13195-023-01314-6. View

Aisen P, Davis K, Berg J, Schafer K, Campbell K, Thomas R . A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000; 54(3):588-93. DOI: 10.1212/wnl.54.3.588. View

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024; 20(5):3708-3821. PMC: 11095490. DOI: 10.1002/alz.13809. View

Perl D . Neuropathology of Alzheimer's disease. Mt Sinai J Med. 2010; 77(1):32-42. PMC: 2918894. DOI: 10.1002/msj.20157. View

Breitner J, Gau B, Welsh K, Plassman B, McDonald W, Helms M . Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994; 44(2):227-32. DOI: 10.1212/wnl.44.2.227. View

Beeri M, Schmeidler J, Lesser G, Maroukian M, West R, Leung S . Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol Aging. 2011; 33(7):1258-64. PMC: 3130103. DOI: 10.1016/j.neurobiolaging.2011.02.011. View

10.

Benito-Leon J, Contador I, Vega S, Villarejo-Galende A, Bermejo-Pareja F . Non-steroidal anti-inflammatory drugs use in older adults decreases risk of Alzheimer's disease mortality. PLoS One. 2019; 14(9):e0222505. PMC: 6748568. DOI: 10.1371/journal.pone.0222505. View

11.

Alisky J . Intrathecal corticosteroids might slow Alzheimer's disease progression. Neuropsychiatr Dis Treat. 2009; 4(5):831-3. PMC: 2626920. DOI: 10.2147/ndt.s3685. View

12.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

13.

Calsolaro V, Edison P . Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016; 12(6):719-32. DOI: 10.1016/j.jalz.2016.02.010. View

14.

Yang S . Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease. Int Neurourol J. 2019; 23(Suppl 2):S54-62. PMC: 6905206. DOI: 10.5213/inj.1938184.092. View

15.

Lupien S, De Leon M, De Santi S, Convit A, Tarshish C, Nair N . Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci. 1999; 1(1):69-73. DOI: 10.1038/271. View

16.

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

17.

McCaulley M, Grush K . Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment. Int J Alzheimers Dis. 2015; 2015:515248. PMC: 4664815. DOI: 10.1155/2015/515248. View

18.

Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, Garcia-Eulate M, Arbizu J . Early- and late-onset Alzheimer disease: Are they the same entity?. Neurologia (Engl Ed). 2015; 33(4):244-253. DOI: 10.1016/j.nrl.2015.08.002. View

19.

Cao J, Hou J, Ping J, Cai D . Advances in developing novel therapeutic strategies for Alzheimer's disease. Mol Neurodegener. 2018; 13(1):64. PMC: 6291983. DOI: 10.1186/s13024-018-0299-8. View

20.

Akwa Y . Steroids and Alzheimer's Disease: Changes Associated with Pathology and Therapeutic Potential. Int J Mol Sci. 2020; 21(13). PMC: 7370115. DOI: 10.3390/ijms21134812. View